Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Adrenocortical Carcinoma 2

Interventions

Mitotane 4Cisplatin 3pembrolizumab 2cixutumumab 2Etoposide 2Doxorubicin 2Dichlorodiphenyldichloroethane 2sodium thiosulfate 1relacorilant 1pegfilgrastim 1milademetan 1gossypol acetic acid 1cabozantinib 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Sunitinib 1Streptozocin 1Platinum 1Nivolumab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Ethane 1Cytoreduction Surgical Procedures 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Adrenocortical Carcinoma × Dichlorodiphenyldichloroethane × Clear all
NCT00304070 2024-02-28

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Children's Oncology Group

Phase 3 Completed
78 enrolled 15 charts
Endocrine

Adrenocortical Carcinoma

NCT00778817 2014-04-29

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
20 enrolled 17 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡